The Global Pharmaceutical Industry is Accelerating; Aptorum Group Has Received Orphan Drug Designation from US FDA for Its SACT-1

HONG KONG, July 26, 2022 – (ACN Newswire) – The aging of the population is accelerating, pharmaceutical technology is constantly updating, and the development of the global pharmaceutical industry continues to accelerate. The pharmaceutical market is expected to maintain a growing trend. According to Frost & Sullivan, the global pharmaceutical market is expected to reach $1,711.4... » read more

Fujitsu and RIKEN start joint research on next-generation IT drug discovery technology using the supercomputer Fugaku and simulation integrated AI
Fujitsu and RIKEN start joint research on next-generation IT drug discovery technology using the supercomputer Fugaku and simulation integrated AI

TOKYO, May 17, 2022 – (JCN Newswire via SEAPRWire.com) – Fujitsu Limited and RIKEN today launched a joint research project on next-generation IT drug discovery technology utilizing the supercomputer Fugaku(1), aiming to accelerate DX (digital transformation) in drug discovery, explore promising new areas in this process, and dramatically reduce development period and costs for new... » read more

Fujitsu and Atmonia Leverage HPC and AI Technology in Joint Project to Contribute to Carbon Neutrality
Fujitsu and Atmonia Leverage HPC and AI Technology in Joint Project to Contribute to Carbon Neutrality

Tokyo and Reykjavík, Iceland, Apr 13, 2022 – (JCN Newswire via SEAPRWire.com) – Fujitsu and Atmonia ehf., an Icelandic start-up company developing a sustainable process for ammonia production, today announced signing of an agreement regarding conduct of joint research to accelerate catalysts development for the clean production of ammonia, leveraging on high-performance computing (HPC) and... » read more

Apollomics Inc. To Host Virtual Investor Events on Wednesday, January 26, 2022 and Thursday, January 27, 2022
Apollomics Inc. To Host Virtual Investor Events on Wednesday, January 26, 2022 and Thursday, January 27, 2022

Foster City, CA, Shanghai and Hangzhou, China, Jan 12, 2022 – (ACN Newswire via SEAPRWire.com) – Apollomics Inc. an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced that the management team will host two upcoming webcasts to accommodate participants from the U.S. and China. Co-Founder, Chairman... » read more

WARC, TikTok and Publicis Groupe release “From Discovery to Purchase: The Role of Community Commerce” a new study revealing the potential of creator-driven marketing for brand growth
WARC, TikTok and Publicis Groupe release “From Discovery to Purchase: The Role of Community Commerce” a new study revealing the potential of creator-driven marketing for brand growth

LONDON, Oct 19, 2021 – (ACN Newswire via SEAPRWire.com) – WARC, in partnership with TikTok (www.tiktok.com) and Publicis Groupe (www.publicisgroupe.com/fr/splash), have today released a new study exploring the role social communities play in influencing purchase decisions, outlining the huge potential for brands to engage with audiences and increase unplanned purchases by narrowing the funnel between... » read more

Hitachi and Axcelead have agreed to start joint development of solutions contributing on more efficient creation of next-generation biopharmaceuticals
Hitachi and Axcelead have agreed to start joint development of solutions contributing on more efficient creation of next-generation biopharmaceuticals

TOKYO, Apr 7, 2021 – (JCN Newswire via SEAPRWire.com) – Hitachi, Ltd. (TSE:6501) and Axcelead, Inc. today announced that they have agreed on a comprehensive collaborative partnership to develop solutions contributing on more efficient creation of next-generation biopharmaceuticals with digital technology and drug discovery platform. Hitachi has also made investment to Drug Discovery Gateway Fund... » read more

Eisai and Wren Therapeutics Enter Into Research Collaboration Agreement for Drug Discovery for Synucleinopathies
Eisai and Wren Therapeutics Enter Into Research Collaboration Agreement for Drug Discovery for Synucleinopathies

TOKYO, Nov 30, 2020 – (JCN Newswire) – Eisai Co., Ltd. and Wren Therapeutics Ltd. today announced that the companies have entered into an exclusive research collaboration agreement aiming to advance the discovery of novel small molecules that target alpha-synuclein for the potential treatment of synucleinopathies including Parkinson’s disease and dementia with Lewy bodies. Wren... » read more

Fujitsu: Establishment of Joint Venture Aimed at the Development of Therapeutics for the Treatment of Coronavirus Disease
Fujitsu: Establishment of Joint Venture Aimed at the Development of Therapeutics for the Treatment of Coronavirus Disease

TOKYO, Nov 13, 2020 – (JCN Newswire) – PeptiDream Inc., a public Kanagawa-based biopharmaceutical company (TSE:4587), Fujitsu Limited (TSE:6702), Mizuho Capital Co., Ltd. which is a consolidated subsidiary of Mizuho Financial Group, Inc., Takenaka Corporation and KISHIDA CHEMICAL CO., LTD. have agreed today to establish PeptiAID Inc., a joint venture company that will research and... » read more